首页> 美国卫生研究院文献>Oncology Reports >Identification of potential prognostic long non-coding RNA signatures based on a competing endogenous RNA network in lung adenocarcinoma
【2h】

Identification of potential prognostic long non-coding RNA signatures based on a competing endogenous RNA network in lung adenocarcinoma

机译:基于竞争性内源性RNA网络的肺腺癌潜在预后性长非编码RNA信号识别

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A number of experimental and computational studies have demonstrated the key roles of long non-coding RNAs (lncRNAs) acting as competing endogenous RNAs (ceRNAs) in the tumorigenesis of lung adenocarcinoma (LUAC). However, there remains a requirement for prognostic candidate biomarkers acting as ceRNAs for the prediction of overall survival in patients with LUAC. The main goal of the present study was to identify novel lncRNAs associated with LUAC overall survival and assess their prognostic values. The study analyzed coding RNA and ncRNA expression profiles of patients with LUAC by retrieving existing RNA-sequencing datasets from The Cancer Genome Atlas database, and 2,507 differentially expressed mRNAs, 1,633 lncRNAs and 113 miRNAs were screened from patients with LUAC compared with those of adjacent normal samples (P<0.01 and |logFC|>2). Of these LUAC-specific RNAs, 134 lncRNAs, 21 miRNAs and 34 mRNAs were used to build an lncRNA-mRNA-miRNA ceRNA network, among which 8 lncRNAs and 9 mRNAs were associated with overall survival in patients with LUAC by acting as ceRNAs. Next, an lncRNA-based prognostic signature was constructed by risk scoring approach based on the expression levels of 9 prognosis-associated lncRNAs using Cox's regression analysis. Moreover, the prognostic capacity of the 9-lncRNA signature was independent of known clinical prognostic factors. These results provide novel insight into the potential of lncRNA ceRNAs to be candidate biomarkers associated with LUAC overall survival.
机译:大量的实验和计算研究已经证明,长的非编码RNA(lncRNA)作为竞争性内源RNA(ceRNA)在肺腺癌(LUAC)的发生中起着关键作用。但是,仍然需要预后性候选生物标记物作为ceRNA来预测LUAC患者的总生存期。本研究的主要目的是鉴定与LUAC总体存活率相关的新型lncRNA,并评估其预后价值。该研究通过从癌症基因组图谱数据库中检索现有的RNA测序数据集,分析了LUAC患者的编码RNA和ncRNA表达谱,与相邻正常人相比,从LUAC患者中筛选了2,507个差异表达的mRNA,1,633个lncRNA和113个miRNA。样本(P <0.01和| logFC |> 2)。在这些LUAC特异的RNA中,使用134个lncRNA,21个miRNA和34个mRNA来构建lncRNA-mRNA-miRNA ceRNA网络,其中8个lncRNA和9个mRNA通过充当ceRNA与LUAC患者的整体生存相关。接下来,使用Cox回归分析,基于9种与预后相关的lncRNA的表达水平,通过风险评分方法构建了基于lncRNA的预后签名。此外,9-lncRNA信号的预后能力与已知的临床预后因素无关。这些结果为lncRNA ceRNA成为与LUAC总体存活率相关的候选生物标志物的潜力提供了新颖的见解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号